“Stop Postponing Your Life Until You Lose Weight and Start Living Now”: Vancouver’s Large as Life Action Group, 1979–1985

Vancouver fat acceptance group Large as Life (LAL) was active between 1979 and 1985. The founding members of LAL met at a Gestalt therapy workshop for fat women only in 1979, but ultimately decided that talking was not enough to resolve the problems they experienced on a day-to-day basis. For these women, fat was not just a feeling but a material problem that could be solved through the development of social sites and services that catered to fat women. These would include fitness classes, fashion shows, clothing swaps and personal development workshops. Using interviews with former Large as Life members, together with articles from the group’s newsletter, The Bolster, this paper examines fat women’s perspectives on femininity, health, and fashion in the 1980s. It argues that the shared practices developed among members of Large as Life are an example of the lived complexity of femininity in the 1980s, and, specifically, offers insight into how women experienced and situated themselves in relation to the beauty and bodily norms of the 1980s.Le groupe pour l’acceptation de l’obésité de Vancouver, Large as Life (LAL), a été actif de 1979 à 1985. Les membres fondatrices du LAL se sont rencontrées lors d’un atelier de thérapie Gestalt à l’intention des femmes obèses en 1979 et ont finalement décidé que la discussion ne suffisait pas pour résoudre les problèmes qu’elles éprouvaient quotidiennement. Pour ces femmes, l’obésité n’était pas uniquement un sentiment, mais un problème matériel qui pouvait se résoudre en élaborant des sites et des services sociaux qui répondraient aux besoins des femmes obèses. Ceux-ci comprendraient des groupes de culture physique, et d’échange de vêtements, des défilés de mode et des ateliers de développement personnel. Au moyen d’entrevues avec d’anciens membres de Large as Life et d’articles du bulletin du groupe, The Bolster, cet article examine les perspectives des femmes obèses par rapport à la féminité, la santé et la mode dans les années 1980. Il fait valoir que les pratiques communes élaborées par les membres de Large as Life sont un exemple de la complexité de la féminité vécue dans les années 1980 et, en particulier, il offre un point de vue sur la façon dont les femmes se sentaient et se situaient elles-mêmes par rapport aux normes des années 1980 relatives a la beauté et à l’apparence physique

Supporting Adolescents on the Edge of Care : The role of short term stays in residential care: an evidence scope

The evidence scope was commissioned by the NSPCC and Action for Children (AFC) to gather material on provision for adolescents on the edge of care and their families. The remit requested a particular focus on innovative approaches, including an exploration of the use of respite stays in residential units. What became apparent from the start of our exploration was the surge in attention over recent years around edge of care needs and provision within policy and research. This has already been captured in a number of recent literature reviews and reports, two of which provide comprehensive and informative discussions of the literature and research currently available on adolescents on the edge of care (see ADCS, 2013 and Bowyer and Wilkinson, 2013). Given the availability of this detailed literature, the aim of this evidence scope was to build upon the available evidence by drawing together some of the key learning from the existing reviews and adding to this knowledge base by gathering new primary data from policy and practice stakeholders and leading academics on the ways that services can best support this group. This involved carrying out surveys and telephone interviews with children’s services providers and experts across the UK and internationally, to gather practice evidence on the range of edge of care provision. This report, therefore, draws together new data based on current practice and learning to enhance evidence from existing sources. In doing so, we hope to further the debate on how edge of care provision for adolescents is currently defined and utilised and to identify scope for its future potential. The evidence scope took place from February to April 2015

Host Galaxies of Luminous Type 2 Quasars at z ~ 0.5

We present deep Gemini GMOS optical spectroscopy of nine luminous quasars at redshifts z ~ 0.5, drawn from the SDSS type 2 quasar sample. Our targets were selected to have high intrinsic luminosities (M_V < -26 mag) as indicated by the [O III] 5007 A emission-line luminosity (L_[O III]). Our sample has a median black hole mass of ~ 10^8.8 M_sun inferred assuming the local M_BH-sigma_* relation and a median Eddington ratio of ~ 0.7, using stellar velocity dispersions sigma_* measured from the G band. We estimate the contamination of the stellar continuum from scattered quasar light based on the strength of broad H-beta, and provide an empirical calibration of the contamination as a function of L_[O III]; the scattered light fraction is ~ 30% of L_5100 for objects with L_[O III] = 10^9.5 L_sun. Population synthesis indicates that young post-starburst populations (< 0.1 Gyr) are prevalent in luminous type 2 quasars, in addition to a relatively old population (> 1 Gyr) which dominates the stellar mass. Broad emission complexes around He II 4686 A with luminosities up to 10^8.3 L_sun are unambiguously detected in three out of the nine targets, indicative of Wolf-Rayet populations. Population synthesis shows that ~ 5-Myr post-starburst populations contribute substantially to the luminosities (> 50% of L_5100) of all three objects with Wolf-Rayet detections. We find two objects with double cores and four with close companions. Our results may suggest that luminous type 2 quasars trace an early stage of galaxy interaction, perhaps responsible for both the quasar and the starburst activity.Comment: 20 pages, 13 figures, 7 tables; accepted to Ap

Mental health service users' experiences of returning to paid employment

Research into mental health and employment has focused largely on people who are unemployed. This paper reports the experiences of 20 clients of employment support agencies who had succeeded in returning to work. A number of barriers to getting back to work were identified, but receiving employment support could enable people to overcome them. There was consistency with previous studies of factors associated with high and low levels of job satisfaction. Even those participants who were less satisfied with their jobs identified benefits and none described any negative effects. The quality of the employment support provided was important, including advice and counselling during the job search, enabling informed choice about disclosure and support in work. Job retention targets are required for funding programmes in addition to placement targets. Further research into the timing and processes of disclosure and into occupational health screening processes would be helpful

Novel IgG-degrading enzymes of the IgdE protease family link substrate specificity to host tropism of <i>Streptococcus</i> species

Recently we have discovered an IgG degrading enzyme of the endemic pig pathogen S. suis designated IgdE that is highly specific for porcine IgG. This protease is the founding member of a novel cysteine protease family assigned C113 in the MEROPS peptidase database. Bioinformatical analyses revealed putative members of the IgdE protease family in eight other Streptococcus species. The genes of the putative IgdE family proteases of S. agalactiae, S. porcinus, S. pseudoporcinus and S. equi subsp. zooepidemicus were cloned for production of recombinant protein into expression vectors. Recombinant proteins of all four IgdE family proteases were proteolytically active against IgG of the respective Streptococcus species hosts, but not against IgG from other tested species or other classes of immunoglobulins, thereby linking the substrate specificity to the known host tropism. The novel IgdE family proteases of S. agalactiae, S. pseudoporcinus and S. equi showed IgG subtype specificity, i.e. IgdE from S. agalactiae and S. pseudoporcinus cleaved human IgG1, while IgdE from S. equi was subtype specific for equine IgG7. Porcine IgG subtype specificities of the IgdE family proteases of S. porcinus and S. pseudoporcinus remain to be determined. Cleavage of porcine IgG by IgdE of S. pseudoporcinus is suggested to be an evolutionary remaining activity reflecting ancestry of the human pathogen to the porcine pathogen S. porcinus. The IgG subtype specificity of bacterial proteases indicates the special importance of these IgG subtypes in counteracting infection or colonization and opportunistic streptococci neutralize such antibodies through expression of IgdE family proteases as putative immune evasion factors. We suggest that IgdE family proteases might be valid vaccine targets against streptococci of both human and veterinary medical concerns and could also be of therapeutic as well as biotechnological use

Existential Loneliness and end-of-life care: A Systematic Review

Contains fulltext : 88662.pdf (publisher's version ) (Closed access)Patients with a life-threatening illness can be confronted with various types of loneliness, one of which is existential loneliness (EL). Since the experience of EL is extremely disruptive, the issue of EL is relevant for the practice of end-of-life care. Still, the literature on EL has generated little discussion and empirical substantiation and has never been systematically reviewed. In order to systematically review the literature, we (1) identified the existential loneliness literature; (2) established an organising framework for the review; (3) conducted a conceptual analysis of existential loneliness; and (4) discussed its relevance for end-of-life care. We found that the EL concept is profoundly unclear. Distinguishing between three dimensions of EL-as a condition, as an experience, and as a process of inner growth-leads to some conceptual clarification. Analysis of these dimensions on the basis of their respective key notions-everpresent, feeling, defence; death, awareness, difficult communication; and inner growth, giving meaning, authenticity-further clarifies the concept. Although none of the key notions are unambiguous, they may function as a starting point for the development of care strategies on EL at the end of life.1 april 201

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

HE-LHC: The High-Energy Large Hadron Collider: Future Circular Collider Conceptual Design Report Volume 4

In response to the 2013 Update of the European Strategy for Particle Physics (EPPSU), the Future Circular Collider (FCC) study was launched as a world-wide international collaboration hosted by CERN. The FCC study covered an energy-frontier hadron collider (FCC-hh), a highest-luminosity high-energy lepton collider (FCC-ee), the corresponding 100 km tunnel infrastructure, as well as the physics opportunities of these two colliders, and a high-energy LHC, based on FCC-hh technology. This document constitutes the third volume of the FCC Conceptual Design Report, devoted to the hadron collider FCC-hh. It summarizes the FCC-hh physics discovery opportunities, presents the FCC-hh accelerator design, performance reach, and staged operation plan, discusses the underlying technologies, the civil engineering and technical infrastructure, and also sketches a possible implementation. Combining ingredients from the Large Hadron Collider (LHC), the high-luminosity LHC upgrade and adding novel technologies and approaches, the FCC-hh design aims at significantly extending the energy frontier to 100 TeV. Its unprecedented centre-of-mass collision energy will make the FCC-hh a unique instrument to explore physics beyond the Standard Model, offering great direct sensitivity to new physics and discoveries